Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients.
Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W, Peng H, Deng Z, Xiao G, Liu X, Na J, Xia D, Yu X, Zhang Z, Xiang B, Huo Y, Yan D, Dong Z, Fang F, Ma Y, Jin G, Su D, Liu X, Li Q, Liao H, Tang C, He J, Tang Z, Zhang S, Qiu B, Yang Z, Yang L, Chen Z, Zeng M, Feng R, Jiao J, Liao Y, Wang T, Wu L, Mi Z, Liu Z, Shi S, Zhang K, Shi W, Zhao Y.
Zhong L, et al.
Cell. 2025 Jan 15:S0092-8674(24)01423-5. doi: 10.1016/j.cell.2024.12.010. Online ahead of print.
Cell. 2025.
PMID: 39826543
Free article.